CalciMedica, Inc. SEC Filings

CalciMedica, Inc. (CALC) increased its at‑the‑market capacity to $9,700,000. The company filed a prospectus supplement to raise the maximum aggregate offering price of common stock that may be issued under its at‑the‑market offering agreement with H.C. Wainwright & Co.

The prior limit under the program was $4,450,000, as referenced in an earlier supplement. A legal opinion covering the $9,700,000 of common stock was included as Exhibit 5.1.

CALC filed a prospectus supplement for its at-the-market program, stating it may offer and sell shares of common stock with an aggregate offering price of up to $9,700,000 from time to time through H.C. Wainwright & Co. as sales agent under Form S-3 General Instruction I.B.6.

The filing cites a public float of approximately $36.3 million, based on 14,399,531 shares outstanding and 10,146,506 shares held by non‑affiliates at a $3.58 closing price on September 9, 2025. The company has sold $2.3 million of securities under I.B.6 during the prior 12 months. The stock last traded at $3.03 on November 5, 2025. Pursuant to I.B.6, public primary sales cannot exceed one‑third of the public float in any 12‑month period while float remains below $75.0 million.

CalciMedica, Inc. (CALC) disclosed a director stock option grant on a Form 4. On 10/13/2025, the reporting person received a Director Stock Option (Right to Buy) for 937 shares of common stock at an exercise price of $3.26 per share, coded A for award.

The option has an expiration date of 10/12/2035 and was reported as Direct (D) ownership with 937 derivative securities beneficially owned following the transaction. The filing notes a vesting schedule: beginning October 1, 2025, 1/3 of the shares subject to the option will vest in equal monthly installments. The option was granted at a price of $0 for the derivative security, consistent with standard equity awards.

Eric W. Roberts, identified as a Director, 10% owner and Chief Business Officer of CalciMedica, Inc. (CALC), reported a purchase of 2,500 shares of the issuer's common stock on 09/18/2025 at a price of $3.07 per share. The Form 4 lists multiple existing direct and indirect holdings across custodial and SPV accounts. The filing was signed by an attorney-in-fact on 09/22/2025.

CalciMedica, Inc. reported that Eric W. Roberts, its chief business officer, director, and a ten percent owner, made an open-market purchase of common stock. On September 15, 2025, a Roth IRA account for his benefit bought 3,400 shares at a weighted average price of $2.6779 per share, with trade prices ranging from $2.65 to $2.70. Following this transaction, that Roth IRA held 81,650 common shares. The filing also updates his other direct and indirect common stock positions, including shares held directly and through multiple IRA and Valence Investments SPV entities.

CalciMedica, Inc. director and chief business officer Eric W. Roberts reported an open-market purchase of 5,000 shares of common stock at $3.12 per share. The shares are held indirectly through an FMTC Custodian Roth IRA for his benefit. The filing also updates his direct and other indirect common stock holdings across several custodial and investment entities.

CalciMedica insider purchase and holdings summary. Eric W. Roberts, who is listed as a director, a 10% owner and Chief Business Officer, reported a purchase of 2,343 shares of CalciMedica common stock on 09/09/2025 at a weighted average price of $3.1488 (price range $2.75–$3.21). The filing lists total beneficial ownership following the reported transactions across multiple accounts and entities: 73,250 shares (FMTC Custodian Roth IRA), 179,706 shares disposed, 49,894 shares (Oppenheimer custodian Roth IRA), 10,661 shares (IRA Financial Trust), 356,989 shares (Valence Investments SPV IV, LLC), 66,228 shares (Valence Investments SPV V, LLC), and 316,109 shares (Valence Investments SPV VI, LLC). The filer signed through an attorney-in-fact.

CalciMedica, Inc. Schedule 13G/A clarifies that a group led by Avenue Venture Opportunities Fund II and affiliated entities reports beneficial ownership of 1,359,553 shares, representing 8.87% of the issuer on a fully diluted basis (13,972,177 shares). The reported position includes 718,390 shares issuable upon conversion of a $2.0 million loan and 641,163 shares issuable upon exercise of warrants.

The Loan and Security Agreement closed on February 28, 2025 for up to $32 million in three tranches; Tranche I funded at closing, Tranche II is available between September 1, 2025 and March 31, 2026 and remained unfunded at the amendment date. The amendment reports that the actual number of common shares held as of the filing is 1,000,358 shares and clarifies conversion rights and voting/dispositive power among the reporting persons.

CalciMedica, Inc. disclosed that a group led by Avenue Venture Opportunities Fund II, L.P. beneficially owns 1,359,553 shares of common stock, representing 8.87% of the fully diluted class based on 13,972,177 shares. The reported holdings include 718,390 shares issuable upon conversion of a $2.0 million loan convertible at a per‑share price of $2.784 and 641,163 shares issuable upon exercise of outstanding warrants. Avenue Capital Management II, L.P. is the manager with sole voting and dispositive power over the Fund's shares but disclaims direct beneficial ownership except to the extent of pecuniary interest. The filing provides required ownership disclosure and related certifications.